Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure

Trial Profile

Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 May 2017

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Heart failure; Hyponatraemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.
    • 23 Jan 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top